Harpoon Therapeutics Inc 's ROA from the third quarter of 2023 to the third quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Harpoon Therapeutics Inc 's ROA in the third quarter of 2023?
Harpoon Therapeutics Inc recorded a cumulative net loss of $-30 million during 12 months ending in the third quarter of 2023, resulting in a negative return on assets (ROA) of -46.14%.

However, within the Healthcare sector 641 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2023 quarter, so far to 4391, from total ROA ranking in the second quarter of 2023 at 4633.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter	(Mar 31 2023) I. Quarter	(Dec 31 2022) IV. Quarter	(Sep 30 2022) III. Quarter
Y / Y Total Assets Change	-43.02 %	-41.64 %	-38.99 %	-53.18 %	-52.2 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-30	-40	-59	-68	-71
Return On Assets (TTM)	-46.14 %	-53.73 %	-68.04 %	-68.24 %	-59.09 %
HARP's Total Ranking	# 4391	# 4633	# 4915	# 5588	# 4982
Total Assets (TTM) in million	48	63	81	73	83
Seq. Total Assets Change	-24.72 %	-21.79 %	11.02 %	-12.83 %	-22.89 %
Seq. Net Income Change	-	-	-	-	-

HARP's 5 Years Annual ROA >> Back to HARP Management Effectiveness >> Compare HARP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 159
Sector	# 642
Overall	# 4324

Return On Assets Statistics
High	Average	Low
-16.16 %	-44.17 %	-67.96 %
(Sep 30 2020)		(Dec 31 2022)

Financial Statements
Harpoon Therapeutics Inc 's Assets	$ 48 million	HARP's Balance sheet
Harpoon Therapeutics Inc 's Income	$ -2 million	Quarterly HARP's Income Statement
HARP's Income by Division		See HARP's Income by Division

Annual Return On Assets	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019	(Dec 31 2016) FY 2018
Y / Y Total Assets Change	-57.58 %	-33.55 %	704.01 %	-	-
Total Assets in million	73	172	258	32	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-68	-117	-50	-56	-11
Annual Return On Assets	-93.05 %	-68.02 %	-19.33 %	-173.03 %	-

HARP's 5 Years Annual ROA >> Back to HARP Management Effectiveness >> Compare HARP ROA to its Competitors

More Return On Assets Ratios
HARP's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
HARP's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for HARP's Competitors
Subscribers only: Roa for Harpoon Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for HARP's Customers

You may also want to know
HARP's Roi	HARP's Inventory Turnover Ratio	HARP's Growth Rates	HARP's Dividend Comparisons
	HARP's Profitability Ratios	HARP's Asset Turnover Ratio	HARP's Dividend Growth
HARP's Roe	HARP's Valuation Ratios	HARP's Financial Strength Ratios	HARP's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2023, within Healthcare Sector

ROA

Date modified: 2026-08-29T17:40:15+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.